<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018885</url>
  </required_header>
  <id_info>
    <org_study_id>F0014-ALA-201809</org_study_id>
    <nct_id>NCT04018885</nct_id>
  </id_info>
  <brief_title>A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris</brief_title>
  <official_title>A Multi-center, Open, Randomized, Parallel Group Study to Assess Safety, Tolerance and Preliminary Efficacy of ALA for the Treatment of Moderate to Severe Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety, tolerability, and preliminary efficacy of
      ALA used with photodynamic therapy for the treatment of moderate to severe acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate in Investigator's Global Assessment (IGA)(8wks)</measure>
    <time_frame>8 weeks after the last treatment</time_frame>
    <description>Proportion of subjects with an assessment of clear or almost clear with at least a 2-grade improvement in IGA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Changes From Baseline in Total Lesion Counts</measure>
    <time_frame>8 weeks after the last treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment Related Adverse Events</measure>
    <time_frame>up to 8 weeks after last treatment</time_frame>
    <description>Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in inflammatory and non-inflammatory lesion counts</measure>
    <time_frame>4, 8 weeks after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate in Investigator's Global Assessment (IGA)(4wks)</measure>
    <time_frame>4 weeks after the last treatment</time_frame>
    <description>Proportion of subjects with an assessment of clear or almost clear with at least a 2-grade improvement in IGA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of acne severity improvement as assessed with the Investigator's Global Assessment (IGA)</measure>
    <time_frame>4, 8 weeks after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life of Subjects from Baseline</measure>
    <time_frame>4, 8 weeks after the last treatment</time_frame>
    <description>Change in Quality of life will be assessed based on Acne-specific Quality of Life Questionnaire to be filled by subjects before and 4/8 weeks after last treatment</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>ALA 2.5% 0.5h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of 2.5% ALA for 0.5 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 2.5% 1.5h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of 2.5% ALA for 1.5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 2.5% 3h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of 2.5% ALA for 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 5% 0.5h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of 5% ALA for 0.5 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 5% 1.5h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of 5% ALA for 1.5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 5% 3h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of 5% ALA for 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 10% 0.5h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of 10% ALA for 0.5 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 10% 1.5h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of 10% ALA for 1.5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA 10% 3h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of 10% ALA for 3 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALA 2.5%</intervention_name>
    <description>Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.</description>
    <arm_group_label>ALA 2.5% 0.5h</arm_group_label>
    <arm_group_label>ALA 2.5% 1.5h</arm_group_label>
    <arm_group_label>ALA 2.5% 3h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALA 5%</intervention_name>
    <description>Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.</description>
    <arm_group_label>ALA 5% 0.5h</arm_group_label>
    <arm_group_label>ALA 5% 1.5h</arm_group_label>
    <arm_group_label>ALA 5% 3h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALA 10%</intervention_name>
    <description>Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.</description>
    <arm_group_label>ALA 10% 0.5h</arm_group_label>
    <arm_group_label>ALA 10% 1.5h</arm_group_label>
    <arm_group_label>ALA 10% 3h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chinese male or female patients aged 18 - 40 years;

          2. Grade III-IV facial acne vulgaris according to the Pillsbury International Improvement
             scale.;

          3. All patients claimed to take effective contraception from 14 days before to 1 month
             after the end of the study, (among those who had used contraceptive two weeks prior to
             the study, the dosage of the drug should remain the same throughout the study) and had
             no fertility or donation of sperm/egg plan;

          4. Informed consents were signed.

        Exclusion Criteria:

          1. Suffering with malignant tumors, cardiac, endocrine, blood, liver, immunity,
             metabolism, urinary system, lungs, nervous system, rheumatism / joint, psychology and
             kidney diseases;

          2. Obviously abnormal liver and kidney function;

          3. Suffering with allergy diseases; suspected or known to have porphyria; allergic to
             studying drugs and / or porphyrin; allergic to visible light; allergic constitution
             (allergic to two or more drugs, food or pollen);

          4. Secondary acne patients, such as occupational acne or acne caused by corticosteroids;

          5. Complicated with other obvious facial skin diseases such as actinic dermatitis,
             psoriasis, seborrheic dermatitis, eczema, skin tumors, etc;

          6. Other diseases that may significantly affect the efficacy evaluation;

          7. Pregnancy, lactation patients;

          8. Exposed to systemic retinoids 2 months prior to the study (acitretin for 6 months);

          9. Exposed to systemic antibiotics, glucocorticoids, spironolactone and other drugs for
             treating acne 4 weeks prior to the study; physical therapy for the treatment of acne;

         10. Exposed to topical retinoids on the face 4 weeks prior to the study or topical
             antibiotics, glucocorticoids, and other topical treatment 2 weeks prior to the study;

         11. Participated in other clinical trials 3 months prior to the study;

         12. Other reasons that the investigator considered inappropriate for participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital for Skin Diseases, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Dermatology Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Hospital of the People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

